| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
IGF-I (24-41) is a fragment of insulin-like growth factor I (IGF-I), which exerts its biological effects primarily through the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase. IGF-1R is activated by IGF-I and IGF-II and mediates the growth-promoting and metabolic effects of IGFs. The IGF-I (24-41) fragment corresponds to a region of the IGF-I molecule that may be involved in receptor binding or biological activity. IGF-I has anabolic, antioxidant, anti-inflammatory, and cytoprotective actions. The peptide fragment is used to study the structure-function relationships of IGF-I and its role in somatic growth and behavioral development.
|
|---|---|
| ln Vitro |
IGF-I (24-41) is used in vitro to study the biological activities of IGF-I fragments. IGF-I has anabolic, antioxidant, anti-inflammatory, and cytoprotective properties. The IGF-I (24-41) fragment regulates somatic growth and behavioral development. The peptide's activity is typically assessed by measuring its effects on cell proliferation, survival, or signaling in cells expressing IGF-1R. The fragment may have reduced or altered activity compared to full-length IGF-I. Comprehensive in vitro activity data for IGF-I (24-41) specifically are available from research publications. The peptide is used to study the structure-function relationships of IGF-I.
|
| ln Vivo |
The hormone IGF-I (24–41) (ICV; 200 ng dosage; 2 µL; postnatal days 2, 4, and 7) controls the development of the body and behavior [2].
In vivo activity of IGF-I (24-41) has been less extensively characterized compared to full-length IGF-I. IGF-I is a trophic factor for both neurons and glial cells and has anabolic, antioxidant, anti-inflammatory, and cytoprotective actions. The IGF-I (24-41) fragment regulates somatic growth and behavioral development. However, comprehensive in vivo efficacy studies using IGF-I (24-41) specifically have not been extensively reported. The peptide is primarily used as a research tool for in vitro studies of IGF-I biology. Further research is needed to determine the in vivo activity of this fragment. |
| Enzyme Assay |
In vitro receptor binding assays for IGF-I (24-41) involve measuring binding affinity to the type 1 IGF receptor (IGF-1R). Membranes from cells expressing IGF-1R are incubated with a radiolabeled IGF-I ligand and varying concentrations of the test peptide. Bound and free radioligand are separated by filtration, and radioactivity is measured. Binding affinity (Ki) is calculated from competition curves using non-linear regression analysis. Alternatively, functional assays can measure receptor activation by assessing IGF-1R phosphorylation (by Western blot) or downstream signaling (AKT, ERK phosphorylation). Cell proliferation assays using IGF-1R-expressing cells can be performed to assess the peptide's ability to stimulate or inhibit cell growth. Each concentration is typically tested in duplicate or triplicate with appropriate positive controls (full-length IGF-I) and vehicle controls.
|
| Cell Assay |
In vitro cellular assays for IGF-I (24-41) are performed using cell lines that express IGF-1R, such as fibroblasts, neuronal cells, or cancer cell lines. Cells are serum-starved and treated with varying concentrations of the peptide. Cell proliferation is measured using [3H]-thymidine incorporation or CellTiter-Glo assays. IGF-1R phosphorylation and downstream signaling (AKT, ERK) are assessed by Western blot using phospho-specific antibodies. Cell survival is assessed under conditions of serum deprivation or stress. Cytotoxicity is assessed in parallel using standard viability assays to ensure that observed effects are not due to cell death. EC50 values for stimulation of proliferation or signaling are calculated from dose-response curves.
|
| Animal Protocol |
Animal/Disease Models: Swiss inbred strain mouse (CD-1), body weight 30-33g (nulliparous male) or 28-30g (nulliparous female) [2]
Doses: 200ng dose; 2 µL Route of Administration: ICV; postnatal Days 2, 4 and 7 (PND) Experimental Results: Increased pup ultrasonic call rate measured on PND8. In vivo animal studies for IGF-I (24-41) have not been extensively reported in the public domain. Full-length IGF-I has been studied in various animal models for its effects on growth, metabolism, and neuroprotection. The IGF-I (24-41) fragment could potentially be evaluated in similar models, but comprehensive studies using this specific fragment have not been widely published. The peptide is primarily used as a research tool for in vitro studies. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of IGF-I (24-41) are characteristic of a peptide. The peptide has a molecular formula of C88H133N27O28 and a molecular weight of 2017.16 g/mol. Its sequence is Tyr-Phe-Asn-Lys-Pro-Thr-Gly-Tyr-Gly-Ser-Ser-Ser-Arg-Arg-Ala-Pro-Gln-Thr. As a peptide, IGF-I (24-41) is susceptible to proteolytic degradation and would have a short half-life in circulation. The peptide is typically administered by injection due to poor oral bioavailability. Comprehensive pharmacokinetic parameters have not been reported for this specific fragment.
|
| Toxicity/Toxicokinetics |
IGF-I (24-41) is intended for laboratory research use only and has not undergone comprehensive toxicology testing. As a peptide fragment of a growth factor, the compound would be expected to have effects on cell proliferation and survival. Standard in vitro cytotoxicity assays in cell lines are typically performed alongside efficacy studies to rule out nonspecific toxicity. In vivo, animals would be monitored for signs of toxicity if the compound were to be evaluated in animal studies. Comprehensive toxicological characterization has not been reported. The peptide is not approved for human use and is strictly intended for research purposes.
|
| References |
|
| Additional Infomation |
IGF-I (24-41) is a synthetic peptide corresponding to amino acid residues 24-41 of insulin-like growth factor I (IGF-I). IGF-I has anabolic, antioxidant, anti-inflammatory, and cytoprotective properties. The peptide has the sequence YFNKPTGYGSSSRRAPQT. IGF-I (24-41) has a molecular formula of C88H133N27O28 and a molecular weight of 2017.16 g/mol. The compound has not entered clinical trials and is available for research purposes only.
|
| Molecular Formula |
C88H133N27O28
|
|---|---|
| Molecular Weight |
2017.16000
|
| Exact Mass |
2015.98
|
| CAS # |
135861-49-3
|
| Related CAS # |
IGF-I (24-41) (TFA)
|
| PubChem CID |
102601632
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
33
|
| Hydrogen Bond Acceptor Count |
32
|
| Rotatable Bond Count |
63
|
| Heavy Atom Count |
143
|
| Complexity |
4330
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=C(C=C5)O)N)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~24.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (49.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4957 mL | 2.4787 mL | 4.9575 mL | |
| 5 mM | 0.0991 mL | 0.4957 mL | 0.9915 mL | |
| 10 mM | 0.0496 mL | 0.2479 mL | 0.4957 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
